Transfusional Hemosiderosis Clinical Trial
Official title:
A Single-arm, Open-label Study of the Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
This single-arm, open-label, multi-center study enrolled 65 patients from approximately 20 centers. All patients who met the study criteria and were taking, beginning or resuming treatment with Deferasirox were allowed. The study will began with a one month run-in phase, where all patients were instructed to take Deferasirox according to their physician's prescribing information.
Following the run-in phase, patients entered a three month, assessment phase. During the assessment phase, patients were given five general options for taking Deferasirox including with or without meals, crushed and added to a soft food or mixed in a liquid of choice. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00631163 -
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
|
Phase 2 | |
| Completed |
NCT00600938 -
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
|
Phase 2 | |
| Withdrawn |
NCT01927913 -
Treatment of Iron Overload Requiring Chelation Therapy
|
Phase 2 | |
| Completed |
NCT01394029 -
Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox
|
N/A |